Phase I/IIa Trial of E-EDV-D682 Nanocells Targeting EGFR in Metastatic PDAC

This randomized study compares the efficacy and safety of E-EDV-D682/GC nanocells in combination with gemcitabine (a ribonucleoside reductase inhibitor) and nab-paclitaxel (a tubulin inhibitor) versus standard therapy in patients with metastatic, EGFR-positive pancreatic ductal adenocarcinoma who have progressed on prior treatment. Sponsored by Engeneic Pty Limited, the trial explores a novel EGFR-targeted nanocell approach as a potential first-in-human strategy to improve survival in this aggressive cancer type.